22 February 2021

Pfizer and BioNTech have submitted new data to the US Food and Drug Administration (FDA) that showed their Covid-19 vaccine was stable when stored between -25°C and -15°C (-13°F to 5°F), which is temperatures of pharmaceutical freezers. This data will be used to support a proposed update to the companies’ US emergency use authorisation (EUA) prescribing information to allow the vaccine to be stored at these temperatures for two weeks as an alternative to a ultra-low temperature freezer of -80°C.

Johnson & Johnson (J&J) has submitted an emergency use listing to the World Health Organization (WHO) for its single-dose Janssen Covid-19 vaccine candidate. The data package submitted includes  interim efficacy and safety results from a Phase III ENSEMBLE clinical trial. This means J&J has completed its rolling data submission to the WHO.

Chugai Pharmaceutical has concluded a license agreement with Roche to develop and market AT-527, a new oral drug for Covid-19, in Japan. Global Phase II clinical studies of AT-527 are currently ongoing in mild to moderate Covid-19 patients. AT-527 was created by Atea Pharmaceuticals in the US, but it is being jointly developed with Roche. As a result of this deal, Chugai now has exclusive rights to develop and market AT-527 in Japan.

According to Nikkei, Fujifilm Holdings will restart clinical trials of Avigan, its antiviral drug for treating Covid-19, in Japan. The drug’s approval was delayed because of inconclusive trial data, according to a Japanese health ministry panel in December 2020. The new study will involve approximately 270 patients and Fujifilm will seek approval again in October 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.